February 7, 2014
A New Tide Approaches
Simeprevir and sofosbuvir both represent a further step in the evolution of more effective, less-toxic HCV treatment options. But they, too, are just the beginning. Numerous direct-acting antiretrovirals are currently moving through the latter stage of the development pipeline, suggesting that the treatment landscape by early 2015 may look as different from the present as the present does from just a few years earlier.
For the notoriously hard-to-treat HCV genotype 1 in particular, Cox states: "It's hard to predict, but right now in advanced testing, there are some combinations that are inteferon-sparing" yet have very high sustained virologic response rates -- and may not even require the use of ribavirin.
Myles Helfand is the editorial director of TheBody.com and TheBodyPRO.com.
Follow Myles on Twitter: @MylesatTheBody.
|What Is the Most Pressing Issue in HIV Care Today?|
|What's New and Notable in HIV Cure Research?|
|HIV/HCV Coinfection Update: From Testing to Treatment|
|HIV Cure Research: Then, Now and in the Future|
|Boy Dies After Receiving Cord Blood Transplant in Attempt to Cure His HIV|
|Very Early HIV Treatment Leads to Another New Case of a Functional Cure|